AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments.
The company was formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel investigational therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder (SAD), which are in Phase 2 clinical development.
Executive Interviews
AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety
Executive Interviews
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i
